An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Trial details
- Registry ID
- NCT06951217
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Pirfenidone Solution
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)NCT06951217 | AVLN | Phase 2 | Recruiting | 2031-12-31Estimated |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 | AVLN | Phase 2 | Active not recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |